BeBetter Med (SHSE:688759) EBITDA: ¥-170.31 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688759 BeBetter Med Inc SHSE:688759
4 GF Score
Price ¥23.20
View Full Analysis

What is BeBetter Med EBITDA?

BeBetter Med SHSE:688759 -17.26% 4 EBITDA is ¥-170.31 Mil as of Mar. 2026. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100.

BeBetter Med's EBITDA for the three months ended in Mar. 2026 was ¥-52.77 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-170.31 Mil.

During the past 3 years, the average EBITDA Growth Rate was 8.20% per year. During the past 5 years, the average EBITDA Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of BeBetter Med was 30.80% per year. The lowest was -46.30% per year. And the median was -14.45% per year.

BeBetter Med's EBITDA per Share for the three months ended in Mar. 2026 was ¥-0.12. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-0.44.

During the past 3 years, the average EBITDA per Share Growth Rate was 10.10% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of BeBetter Med was 30.20% per year. The lowest was -37.10% per year. And the median was 10.10% per year.

BeBetter Med  (SHSE:688759) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


BeBetter Med EBITDA Related Terms


BeBetter Med EBITDA Historical Data

* Premium members only.

The historical data trend for BeBetter Med's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeBetter Med EBITDA Chart

BeBetter Med Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA
Get a 7-Day Free Trial -134.38 -183.68 -163.46 -44.45 -141.88

BeBetter Med Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.19 -37.59 -33.55 -46.40 -52.77

SHSE:688759 vs VRTX, REGN, RVMD: EBITDA Comparison

For the Biotechnology subindustry, BeBetter Med's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeBetter Med EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeBetter Med's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BeBetter Med's EV-to-EBITDA falls into.


SHSE:688759
4GF Score
BeBetter Med Inc SHSE:688759
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BeBetter Med's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

BeBetter Med's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, BeBetter Med's EBITDA was ¥-141.88 Mil.

BeBetter Med's EBITDA for the quarter that ended in Mar. 2026 is calculated as

BeBetter Med's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, BeBetter Med's EBITDA was ¥-52.77 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-170.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of ¥-170.31 Mil mean?
BeBetter Med (SHSE:688759) has a EBITDA of ¥-170.31 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on BeBetter Med.
Is BeBetter Med's EBITDA too high?
BeBetter Med's current EBITDA is ¥-170.31 Mil. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's EBITDA compare to VRTX and REGN?
BeBetter Med's EBITDA of ¥-170.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Biotechnology company?
A good EBITDA depends on the Biotechnology industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on BeBetter Med. BeBetter Med's current EBITDA is ¥-170.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current EBITDA of ¥-170.31 Mil. The current EBITDA is ¥-170.31 Mil. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current EBITDA is ¥-170.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BeBetter Med Business Description

Address No. 25 Yayingshi Road, Room 802, 8th Floor, Building A-3, Science City, High-tech Industrial Development Zone, Guangzhou, Guangdong, CHN, 510663
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score

Get the complete analysis for SHSE:688759

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥23.20
Price